Asciminib HCl (ABL001; ABL-001; Scemblix), the hydrochloride salt of Asciminib, is an allosteric inhibitor of BCR-ABL1 that has been approved FDA on Oct 29th 2021 for treating Philadelphia chromosome-positive CML (chronic myeloid leukemia).

纯度：≥98%

CAS：2119669-71-3